DM industry expresses interest in high-risk infant management

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.396, 2003-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacologic Management of High-Risk Neuroblastoma in Children

By Ganeshan Veena R. Schor Nina F.

Pediatric Drugs, Vol. 13, Iss. 4, 2011-08 ,pp. : 245-255

Adis International

Access to resources Recommend Favorite

Assessment and management of acute pain in high-risk neonates

By Gibbins Sharyn Stevens Bonnie Asztalos Elizabeth

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 4, 2003-04 ,pp. : 475-483

Informa Healthcare

Access to resources Recommend Favorite

Adjuvant Therapy for High-Risk Gastrointestinal Stromal Tumour: Considerations for Optimal Management

By Joensuu Heikki

Drugs, Vol. 72, Iss. 15, 2012-10 ,pp. : 1953-1963

Adis International

Access to resources Recommend Favorite

Surging employer interest in DM

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 298, 2001-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Hormesis and High-Risk Groups

By Calabrese E.J. Baldwin L.A.

Regulatory Toxicology and Pharmacology, Vol. 35, Iss. 3, 2002-06 ,pp. : 414-428

Academic Press

Access to resources Recommend Favorite